The abstract is read at the publisher; the summary is JClub's.
C6-DPC, an AI-designed synthetic minibinder cocktail, drives efficient human fibroblast-to-muscle transdifferentiation with robust structural and metabolic maturation, including high twitch and tetanic forces.
- Why it matters: Direct myogenic somatic cell reprogramming is limited by lack of control over the extracellular signaling logic that determines cell fate.
- What they did: The team screened de novo minibinders to find C6-DPC, then mapped receptor signaling changes by activating pro-myogenic FGFR1/2c and suppressing anti-myogenic inputs via ALK1 and TGFBR2, with ALK1 depletion and gp130 inhibition tested as checkpoints.
- The result: C6-DPC reprogramming is linked to FGFR1/2c activation and ALK1/TGFBR2 suppression, while gp130 signaling inhibition further enhances conversion, enabling engineered tissues to produce functional contractile forces in wild-type and dystrophin-deficient human cells.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.